Three Cheap Speculative Bets
Thursday turned out to a great day for the speculative part of my portfolio. My position in Human Genome Sciences (HGSI) doubled as the company spurned GlaxoSmithKline's (GSK) buyout offer of $13 a share. I was fortunate to pick up some shares late last year for $7 and sold them for $14 yesterday.
Human Genome Sciences is typical of some of my small-cap picks -- that is, a relatively underfollowed stock that has seen much better days and a much higher stock price. The majority of times, the company is currently not making money or just breaking even but has prospects for a much brighter future and a much higher stock price. As is typical in the small-cap space, the stock can go sideways for a long time before some piece of good news or M&A activity causes it to skyrocket....481 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.